Cysal Overview

  • Founded
  • 2012

Founded
  • Status
  • Private

  • Employees
  • 2

Employees
  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Cysal General Information

Description

Developer of biotechnological products designed to provide assistance in the production of dipeptides. The company's products focus on developing, optimizing, and licensing microbial metabolic diversity and fermentation processes for biopolymers and low-molecular-weight compounds, enabling researchers to replace chemical approaches for the production of specialty and base commodities.

Contact Information

Website
www.cysal.de
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Specialty Chemicals
Drug Discovery
Primary Office
  • Mendelstraße 11
  • 48149 Munster
  • Germany
+49 0251 0000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cysal Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Mar-2021 00.000 Completed Generating Revenue
2. Seed Round 08-Nov-2012 00.000 00.000 00.000 Completed Generating Revenue
1. Grant Completed Startup
To view Cysal’s complete valuation and funding history, request access »

Cysal Patents

Cysal Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3056156-A1 Aspartyl-dipeptides for skin care and cosmetic use Pending 24-Mar-2016 00000000
EP-3439626-A1 Aspartyl-dipeptides for skin care and cosmetic use Active 24-Mar-2016 00000000
EP-3439626-B1 Aspartyl-dipeptides for skin care and cosmetic use Active 24-Mar-2016 00000000
ES-2859651-T3 Aspartyl dipeptides for skin care and cosmetic use Active 24-Mar-2016 00000000
US-11020337-B2 Aspartyl-dipeptides for skin care and cosmetic use Active 24-Mar-2016 A61K8/64
To view Cysal’s complete patent history, request access »

Cysal Executive Team (3)

Name Title Board Seat Contact Info
Ahmed Sallam Co-Founder, Chief Executive Officer & Managing Director
You’re viewing 1 of 3 executive team members. Get the full list »

Cysal Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cysal Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
eCAPITAL entrepreneurial Partners Venture Capital Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
Federal Ministry for Economic Affairs and Energy Limited Partner 000 0000 000000 0
To view Cysal’s complete investors history, request access »